ArticleThe Journal of experimental medicine1992
Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells.
Article in The Journal of experimental medicine, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 67 citations in OpenAlex.
- Murine models to study human NK cells in human solid tumors.Frontiers in immunology · 2023Review
- Next Generation Natural Killer Cells for Cancer Immunotherapy.Frontiers in immunology · 2022Review
- Paths taken towards NK cell-mediated immunotherapy of human cancer-a personal reflection.Scandinavian journal of immunology · 2021Review
- Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition.Immunogenetics · 2017Review
- Natural killer cells in non-hematopoietic malignancies.Frontiers in immunology · 2012Article
- NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy.Cancer immunology, immunotherapy : CII · 2008Review
- Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model.Cancer immunology, immunotherapy : CII · 2008Article
- The MHC class I peptide repertoire is molded by the transcriptome.The Journal of experimental medicine · 2008Article
- H2-M3 major histocompatibility complex class Ib-restricted CD8 T cells induced by Salmonella enterica serovar Typhimurium infection recognize proteins released by Salmonella serovar Typhimurium.Infection and immunity · 2005Article
- Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses.The Journal of experimental medicine · 2000Article
- Major histocompatibility complex (MHC) class I KbDb -/- deficient mice possess functional CD8+ T cells and natural killer cells.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- The molecular basis of natural killer (NK) cell recognition and function.Journal of clinical immunology · 1996Review
- Inhibition of natural killer cell cytotoxicity by cell growth-related molecules.Japanese journal of cancer research : Gann · 1996Article
- A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.The Journal of experimental medicine · 1995Article
- In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.The Journal of experimental medicine · 1994Article
- The CD8+ T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I.The Journal of experimental medicine · 1994Article
- Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type.The Journal of experimental medicine · 1993Article
- Expression of beta 2-microglobulin by human benign and malignant mesenchymal and neurogenic tumours.International journal of experimental pathology · 1993Article
- Antiviral immune responses of lymphocytic choriomeningitis virus-infected mice lacking CD8+ T lymphocytes because of disruption of the beta 2-microglobulin gene.Journal of virology · 1993Article
- Four decades of glucocorticosteroid immunosuppression.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 1993Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
It has frequently been suggested that loss of beta 2-microglobulin (beta 2m) in tumor cells may lead to malignant progression due to escape from immunological recognition. Here, we directly tested the role of beta 2m expression in tumorigenicity. A beta 2 m loss mutant (C4.4-25-), selected from the murine lymphoma EL-4, showed a marked reduction in tumorigenicity as compared with EL-4 in normal C57B1/6 (B6) mice. The reduced tumorigenicity was directly related to beta 2 m expression. Transfection of an intact murine beta 2m gene markedly increased the tumorigenic potential. The reduced tumorigenicity of C4.4-25- compared with beta 2m transfected cells was observed also in athymic B6 nu/nu mice, but was abolished in B6 mice depleted of natural killer (NK) 1.1-positive cells. These results show that restoration of beta 2m expression can promote tumorigenicity and demonstrate for the first time that induction of major histocompatibility complex class I expression by transfection can lead to escape from NK cells in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.